𝔖 Bobbio Scriptorium

✦ LIBER ✦

Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants

✍ Scribed by Aline H. Saad; Daryl D. DePestel; Peggy L. Carver

Book ID: 115049203
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 102 KB
Volume: 26
Category: Article
ISSN: 0277-0008
DOI: 10.1592/phco.26.12.1730

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An evidence-based assessment of the clin

An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists

✍ Eric N. van Roon; Patricia M.L.A. van den Bemt; Tim L.Th.A. Jansen; Nella M. Hou 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 145 KB

Lack of a clinically significant drug-dr

Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

✍ de Kanter, C. T. M. M.; Colbers, A. P. H.; Blonk, M. I.; Verweij-van Wissen, C. 📂 Article 📅 2013 🏛 Oxford University Press 🌐 English ⚖ 325 KB

Voltammetric and electrochemical gravime

Voltammetric and electrochemical gravimetric selective detection of interactions between Tl(I) and guanine and the influence on activity of DNA drug-intercalators

✍ Nowicka, Anna M.; Mackiewicz, Marcin; Matysiak, Edyta; Krasnodebska-Ostrega, Bea 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 949 KB

Elucidation of the biochemical basis for

Elucidation of the biochemical basis for a clinical drug–drug interaction between atorvastatin and 5-( N -(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methyl benzoic acid (CP-778 875), a subtype selective agonist of the peroxisome proliferator-activated receptor alpha

✍ Kalgutkar, Amit S.; Chen, Danny; Varma, Manthena V.; Feng, Bo; Terra, Steven G.; 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 349 KB

Drug interactions between the proteasome

Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF), and TNF-related apoptosis-inducing ligand (TRAIL) in prostate cancer: An J, Sun Y-P, Adams J, Fisher M, Belldegrun A, Rettig MB, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA [J An, Y-PS, MF, MBR]; Millennium Pharmaceuticals, Inc., Cambridge, MA [J Adams]; and University of California at Los Angeles School of Medicine, Los Angeles, CA [AB, MBR]. Clinical Cancer Research 2003;9:4537–4545

✍ Gurkamal Chatta 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 18 KB